leusynergy and semaglutide Approaches for half-life extension of GLP-1 agonists. (a) Liraglutide leusynergy and semaglutide Glucagon‐like peptide‐1

The minimum BMI for semaglutide (Wegovy) under FDA labeling is 30 without any additional conditions, or 27 with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia

Any temperature excursion above 8C denatures the peptide structure, rendering timing optimisation meaningless

A study of compounded GLP-1 preparations found that some contained as little as 60% of the labeled active ingredient

We appreciate the many Members of Congress and staff who took the time to engage on these important issues, including Congressman Glenn Grothman and his team

This therapy is used as part of a clinician-guided approach to support healthy aging and daily wellness

The concerns are limited but real